Literature DB >> 25897075

Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.

Junghui Koo1, Xiaoyun Wu1, Zixu Mao2, Fadlo R Khuri1, Shi-Yong Sun3.   

Abstract

Rictor, an essential component of mTOR complex 2 (mTORC2), plays a pivotal role in regulating mTOR signaling and other biological functions. Posttranslational regulation of rictor (e.g. via degradation) and its underlying mechanism are largely undefined and thus are the focus of this study. Chemical inhibition of the proteasome increased rictor ubiquitination and levels. Consistently, inhibition of FBXW7 with various genetic means including knockdown, knock-out, and enforced expression of a dominant-negative mutant inhibited rictor ubiquitination and increased rictor levels, whereas enforced expression of FBXW7 decreased rictor stability and levels. Moreover, we detected an interaction between FBXW7 and rictor. Hence, rictor is degraded through an FBXW7-mediated ubiquitination/proteasome mechanism. We show that this process is dependent on glycogen synthase kinase 3 (GSK3): GSK3 was associated with rictor and directly phosphorylated the Thr-1695 site in a putative CDC4 phospho-degron motif of rictor; mutation of this site impaired the interaction between rictor and FBXW7, decreased rictor ubiquitination, and increased rictor stability. Finally, enforced activation of Akt enhanced rictor levels and increased mTORC2 activity as evidenced by increased formation of mTORC2 and elevated phosphorylation of Akt, SGK1, and PKCα. Hence we suggest that PI3K/Akt signaling may positively regulate mTORC2 signaling, likely through suppressing GSK3-dependent rictor degradation.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Akt PKB; FBXW7; GSK3; mTOR complex (mTORC); protein degradation; rictor; signal transduction; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2015        PMID: 25897075      PMCID: PMC4447982          DOI: 10.1074/jbc.M114.633057

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Authors:  Masayoshi Yada; Shigetsugu Hatakeyama; Takumi Kamura; Masaaki Nishiyama; Ryosuke Tsunematsu; Hiroyuki Imaki; Noriko Ishida; Fumihiko Okumura; Keiko Nakayama; Keiichi I Nakayama
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

Review 2.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

3.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

4.  Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation.

Authors:  Chie Kanei-Ishii; Teruaki Nomura; Tsuyoshi Takagi; Nobumoto Watanabe; Keiichi I Nakayama; Shunsuke Ishii
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

5.  Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells.

Authors:  S Y Sun; P Yue; G S Wu; W S El-Deiry; B Shroot; W K Hong; R Lotan
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

6.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Authors:  Jian-Hua Mao; Jesus Perez-Losada; Di Wu; Reyno Delrosario; Ryosuke Tsunematsu; Keiichi I Nakayama; Ken Brown; Sheila Bryson; Allan Balmain
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

Review 7.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.

Authors:  C A Sparks; D A Guertin
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

8.  Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.

Authors:  Lei Fu; Young-Ae Kim; Xuerong Wang; Xiaoyun Wu; Ping Yue; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

9.  The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.

Authors:  Heath A Elrod; Yi-Dan Lin; Ping Yue; Xuerong Wang; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cancer Ther       Date:  2007-06-29       Impact factor: 6.261

10.  Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.

Authors:  Keunwook Lee; Ki Taek Nam; Sung Hoon Cho; Prathyusha Gudapati; Yoonha Hwang; Do-Sim Park; Ross Potter; Jin Chen; Emmanuel Volanakis; Mark Boothby
Journal:  J Exp Med       Date:  2012-04-02       Impact factor: 14.307

View more
  33 in total

1.  c-Jun N-terminal kinase (JNK)-mediated induction of mSin1 expression and mTORC2 activation in mesenchymal cells during fibrosis.

Authors:  Natalie M Walker; Serina M Mazzoni; Ragini Vittal; Diane C Fingar; Vibha N Lama
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

Review 2.  An expanding GSK3 network: implications for aging research.

Authors:  Dylan C Souder; Rozalyn M Anderson
Journal:  Geroscience       Date:  2019-07-17       Impact factor: 7.713

Review 3.  mTOR in Lung Neoplasms.

Authors:  Ildiko Krencz; Anna Sebestyen; Andras Khoor
Journal:  Pathol Oncol Res       Date:  2020-02-03       Impact factor: 3.201

4.  PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.

Authors:  Carole Beck; José Manuel Rodriguez-Vargas; Christian Boehler; Isabelle Robert; Vincent Heyer; Najat Hanini; Laurent R Gauthier; Agnès Tissier; Valérie Schreiber; Mikael Elofsson; Bernardo Reina San Martin; Françoise Dantzer
Journal:  Cell Death Differ       Date:  2018-11-15       Impact factor: 15.828

5.  CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.

Authors:  Xin Jin; Chong Yang; Ping Fan; Jun Xiao; Wanli Zhang; Sudong Zhan; Tao Liu; Dejie Wang; Heshui Wu
Journal:  J Biol Chem       Date:  2017-02-27       Impact factor: 5.157

Review 6.  Proteomics of Long-Lived Mammals.

Authors:  Gregory Tombline; Jonathan Gigas; Nicholas Macoretta; Max Zacher; Stephan Emmrich; Yang Zhao; Andrei Seluanov; Vera Gorbunova
Journal:  Proteomics       Date:  2020-01-09       Impact factor: 3.984

Review 7.  Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes.

Authors:  Mahdi Rizk; Zahraa Saker; Hisham F Bahmad; Sanaa Nabha; Hayat Harati; Youssef Fares
Journal:  Mol Biol Rep       Date:  2021-03-01       Impact factor: 2.316

8.  PARP3 comes to light as a prime target in cancer therapy.

Authors:  José Manuel Rodriguez-Vargas; Léonel Nguekeu-Zebaze; Françoise Dantzer
Journal:  Cell Cycle       Date:  2019-05-29       Impact factor: 4.534

9.  Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.

Authors:  Guoqing Qian; Jianping Guo; Karin A Vallega; Changjiang Hu; Zhen Chen; Yunfu Deng; Qiming Wang; Songqing Fan; Suresh S Ramalingam; Taofeek K Owonikoko; Wenyi Wei; Shi-Yong Sun
Journal:  Mol Cancer Res       Date:  2021-06-28       Impact factor: 5.852

10.  VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma.

Authors:  Athina Ganner; Christina Gehrke; Marinella Klein; Lena Thegtmeier; Tanja Matulenski; Laura Wingendorf; Lu Wang; Felicitas Pilz; Lars Greidl; Lisa Meid; Fruzsina Kotsis; Gerd Walz; Ian J Frew; Elke Neumann-Haefelin
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.